再鼎医药Zai Lab Limited (ZLAB) 2021年年度报告「NASDAQ」.pdf

1、2021 Annual Report2021 Annual ReportZai Lab Limited(incorporated in the Cayman Islands with limited liability)HKEX:9688NASDAQ:ZLABCONTENTSCHAIRPERSONS STATEMENT IICORPORATE INFORMATION VFINANCIAL HIGHLIGHTS VIIEXEMPTIONS AND WAIVERS VIIIRESEARCH AND DEVELOPMENT ACTIVITIES XINDEPENDENT AUDITORS REPOR

2、T XICONSOLIDATED FINANCIAL STATEMENTS XVIFORM 10-K LXXIIADDITIONAL INFORMATION LXXIIIIICHAIRPERSONS STATEMENTSamantha Du,PhDFounder,Chairpersonand Chief Executive OfficerMarch 2,2022Dear Zai Lab Shareholders,Id like to begin by reminding you of who we are,and where we are going,at Zai Lab.Zai Lab is

3、 already a fully integrated and leading biopharma company in China.And we will leverage our China strength to become a leading global biopharmaceutical company.China is the second largest and a fast-growing pharmaceutical market.The Chinese population accounts for nearly one fifth of the world popul

4、ation,and it is aging rapidly.The need for innovative medicines that can transform treatment in areas of high unmet need in China has never been greater.We at Zai Lab were the first to see the opportunity to bring an unmatched portfolio of medicines to China to address this great need.We rapidly and

5、 purposefully seized a once-in-a-generation opportunity to build Zai Lab into a biopharma leader,first in China,and then in the world.We built our business around four key elements:a biotech mindset,pharma quality,Zai lab speed,and global talent.Since I founded the company eight years ago,we have bu

6、ilt a portfolio and pipeline of 28 products,including 11 that were internally developed and have global rights and four that are now marketed.We believe few companies can achieve this kind of growth in such a short period of time.But what we are most proud of is not the quantity of our products,but